Randomized controlled trialHumanClinical Trial, Phase II

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

Lancet (London, England), 2023 Aug 5. Frias JP, Hsia S, Eyde S and 8 others.

Study type

Randomized controlled trial · Clinical Trial, Phase II

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Lancet (London, England)

Published

2023 Aug 5

PubMed

PMID 37369232 ↗

DOI

10.1016/S0140-6736(23)01302-8 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Orforglipron →

Indexed under

MeSH terms assigned by the National Library of Medicine.

MaleAdultHumansFemaleMiddle AgedDiabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorTreatment OutcomeGlucagon-Like PeptidesHypoglycemiaBody Weight

Other papers on Orforglipron

Randomized controlled trial · 2026

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

Randomized controlled trial · 2026

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

Randomized controlled trial · 2026

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial

Randomized controlled trial · 2025

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Randomized controlled trial · 2025

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Randomized controlled trial · 2023

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page